Junior/Mid-Level Software Engineer, Sable Bio
£50-75k
+ Equity grants and/or annual bonus
More information about location
1-5 days a week in office (Spitalfields, London)
Comprehensive target safety intelligence in one place
Be an early applicant
Comprehensive target safety intelligence in one place
1-20 employees
Be an early applicant
£50-75k
+ Equity grants and/or annual bonus
More information about location
1-5 days a week in office (Spitalfields, London)
1-20 employees
Company mission
Navigate target safety with augmented intelligence.
Jump to section
Company mission
Navigate target safety with augmented intelligence.
20% female employees
Our take
Sable Bio is stepping into an essential area of biotechnology, where drug safety is a top priority. As demand for new, safer medicines rises, toxicity-related issues often slow down drug development, causing costly delays or failures. With AI and data-driven solutions gaining traction, there's a real opportunity to make safety assessments faster and more efficient.
What makes Sable unique is its use of AI to improve drug safety assessments. With this, Sable analyzes various biomedical data sets to detect potential toxicity in new medicines before human trials. By tapping into the scientific literature and diverse data sources, it spots safety risks quicker, helping drug developers make better decisions and save them time and money.
The company has secured substantial funding, which will help it expand its technology and form key partnerships with biotech, pharma, and healthtech companies. As Sable continues to grow, its platform has the potential to transform drug development by reducing risks and improving patient outcomes.
Kirsty
Company Specialist at Welcome to the Jungle
Benefits
- Every Friday afternoon free for personal development
- Private medical plan
- Annual training budget for professional development
- Opportunity to shape the future of our company and grow as we grow
Company values
- We are differentiators
- We are adaptable
- We are science-led
- We are transparent
- We are focussed
- We are prudent
Funding (1 round)
Jan 2024
$1.9m
Early VC
Total funding: $1.9m
Leadership
Alex de Giorgio
(Co-Founder & CEO)Prior to founding Sable, Alex worked at BenevolentAI, leading multiple disease deployments, and pioneering new methods for relationship extraction.
Josh Almond-Thynne
(Co-Founder & CSO)Prior to founding Sable, Josh helped deliver two pre-clinical candidates as a medicinal chemist at BenevolentAI. He pioneered the use of unstructured data in medicinal chemistry.
Olly Oechsle
(CTO)Prior to joining Sable, Olly spent eight years at BenevolentAI working on applications, data pipelines and Natural Language Processing (NLP) techniques, as VP of Product Engineering.
Office
Jobs (3)
Software Engineering